Monitor daily ATM sales volume via subsequent 8-K filings or prospectus supplements. The pace of sales will determine the speed of dilution. Given the company's small market cap and pre-revenue status, continued ATM activity suggests limited access to non-dilutive financing.
SNGX drugs
SNGX drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 29 $0.4000entry
- T+1 · 5mo ago −1.00%α −1.78% · $0.3960
- T+5 · 4mo ago −3.80%α −5.19% · $0.3848
- T+20 · 4mo ago −7.17%α −6.90% · $0.3713
- T+60 · 8w ago −3.75%α −8.14% · $0.3850
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Soligenix filed a prospectus supplement to increase its at-the-market (ATM) equity offering capacity by $2.5 million, bringing total authorized under the Rodman & Renshaw sales agreement to $8.906 million. The company has already sold approximately $6.234 million of shares under prior supplements, meaning up to $2.672 million in additional common stock could be issued. For a $9 million market cap company, this represents potential dilution of ~28% and signals ongoing cash needs.
Key Facts
- ATM offering capacity increased by $2.5 million to a total of $8.906 million under the Sales Agreement with Rodman & Renshaw LLC.
- Prior sales of approximately $6.234 million of common stock had been completed under earlier prospectus supplements covering up to $6.406 million.
- Up to $2.672 million in additional shares may be sold at market prices, representing roughly 28% of the current $9 million market cap.
Financial Impact
Potential dilution of up to ~28% of current market cap if the full $2.5 million in additional shares are sold at current prices.
Risk Factors
- Further dilution from ongoing ATM sales could pressure the stock price.
- Cash burn may necessitate additional equity raises beyond this ATM increase.
- Lack of revenue or near-term catalysts increases reliance on equity financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-078251 |
| Document: sngx-20260626xex5d1.htm | 0001104659-26-078251 |
| Document: 0001104659-26-078251-index-headers.html | 0001104659-26-078251 |
| Document: 0001104659-26-078251-index.html | 0001104659-26-078251 |
| Document: 0001104659-26-078251.txt | 0001104659-26-078251 |
Track record
7 reports on SNGX
4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +69.30% at T+20 after the Apr 3, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $0.3350 Now $0.2900 −13.43% settles Feb 4
- Nov 2, 202614d ago SC 13G/A Neutral 2/10 Entry $0.3612 Now $0.2900 −19.71% settles Jan 29
- Jun 26, 202620w ago 8-K Bearish 6/10 Viewing Entry $0.4000 to $0.3850 Now $0.2900 +27.50% ▲ +3.75% +8.14% vs SPY
- Jun 26, 202620w ago 424B5 Bearish 7/10 Entry $0.4000 to $0.3850 Now $0.2900 +27.50% ▲ +3.75% +8.14% vs SPY
- May 28, 202624w ago 8-K Bearish 5/10 Entry $0.9100 to $0.4047 Now $0.2900 +68.13% ▲ +55.53% +56.71% vs SPY
- May 28, 202624w ago 424B5 Bearish 6/10 Entry $0.9100 to $0.4047 Now $0.2900 +68.13% ▲ +55.53% +56.71% vs SPY
- Apr 3, 202632w ago EFFECT Bearish 6/10 Entry $1.14 to $0.3970 Now $0.2900 +74.56% ▲ +65.18% +78.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers